Ownership history in MPM BioImpact LLC · 7 quarters on record
This page tracks every 13F SEC filing in which MPM BioImpact LLC reported a position in Ultragenyx Pharmaceutical Inc (RARE). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | UNCHANGED | 395,700 | — | 0% | 1.95% | $11.9M | $30.08 |
| 2025 Q2 | REDUCED | 395,700 | -2,745 | -0.7% | 2.49% | $14.4M | $36.36 |
| 2025 Q1 | ADDED | 398,445 | +7,427 | +1.9% | 2.48% | $14.4M | $36.21 |
| 2024 Q4 | ADDED | 391,018 | +61,285 | +18.6% | 2.34% | $16.5M | $42.07 |
| 2024 Q3 | REDUCED | 329,733 | -50,819 | -13.4% | 2.75% | $18.3M | $55.55 |
| 2024 Q2 | ADDED | 380,552 | +134,962 | +55.0% | 2.43% | $15.6M | $41.10 |
| 2024 Q1 | INITIATED | 245,590 | — | — | 1.84% | $11.5M | — |
As of 2025 Q4 — sorted by position size